31. Hervouet E, Cizkova A, Demont J, Vojtiskova A, Pecina P, et al. (2008) HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcino- genesis 29: 1528–1537. 32. Semenza GL (2007) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39: 231–234. 33. Schuetz AN, Yin-Goen Q, Amin MB, Moreno CS, Cohen C, et al. (2005) Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 7: 206–218. 34. Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19: 3–10. 35. Johnson GB, Brunn GJ, Tang AH, Platt JL (2003) Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol 24: 19–24. 36. Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171–179. 37. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, et al. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223–2233. 38. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, et al. (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177: 1272–1281. 39. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370–7377. 40. Petit I, Jin D, Rafii S (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28: 299–307. 41. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, et al. (2006) Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5: 56. 42. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832–1837. 43. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391–1402. 44. Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, et al. (2007) CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 67: 7518–7524. 45. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, et al. (2003) T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 550: 79–83. 46. Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, et al. (2007) Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 13: 5703–5709. 47. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, et al. (2007) Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 13: 1749–1756. 48. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, et al. (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non- clear-cell histology. J Clin Oncol 20: 2376–2381. 49. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB (2005) Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28: 488–495. Signature in Renal Carcinoma 50. Zhao H, Zongming M, Tibshirani R, Higgins JP, Ljungberg B, et al. (2009) Alteration of gene expression signatures of cortical differentiation and wound response in lethal clear cell renal cell carcinomas. PLoS One 4: e6039. 51. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial- mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–715. 52. Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177–186. 53. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992–1000. 54. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645–659. 55. Airik R, Karner M, Karis A, Karner J (2005) Gene expression analysis of Gata3-/- mice by using cDNA microarray technology. Life Sci 76: 2559–2568. 56. Labastie MC, Catala M, Gregoire JM, Peault B (1995) The GATA-3 gene is expressed during human kidney embryogenesis. Kidney Int 47: 1597–1603. 57. Grote D, Souabni A, Busslinger M, Bouchard M (2006) Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development 133: 53–61. 58. Ferraris S, Del Monaco AG, Garelli E, Carando A, De Vito B, et al. (2009) HDR syndrome: a novel ‘‘de novo’’ mutation in GATA3 gene. Am J Med Genet A 149A: 770–775. 59. Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, et al. (2000) GATA3 haplo-insufficiency causes human HDR syndrome. Nature 406: 419–422. 60. Wang L, Wildt KF, Zhu J, Zhang X, Feigenbaum L, et al. (2008) Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4(+) T cells. Nat Immunol 9: 1122–1130. 61. UniProt T (2009) The Universal Protein Resource (UniProt) 2009. Nucleic Acids Res 37: D169–174. 62. Moser M, Pscherer A, Roth C, Becker J, Mucher G, et al. (1997) Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev 11: 1938–1948. 63. Seo KW (2007) Dmrt2 and Pax3 double-knockout mice show severe defects in embryonic myogenesis. Comp Med 57: 460–468. 64. Ottolenghi C, Veitia R, Barbieri M, Fellous M, McElreavey K (2000) The human doublesex-related gene, DMRT2, is homologous to a gene involved in somitogenesis and encodes a potential bicistronic transcript. Genomics 64: 179–186. 65. Ounap K, Uibo O, Zordania R, Kiho L, Ilus T, et al. (2004) Three patients with 9p deletions including DMRT1 and DMRT2: a girl with XY complement, bilateral ovotestes, and extreme growth retardation, and two XX females with normal pubertal development. Am J Med Genet A 130A: 415–423. 66. Lipschutz JH (1998) Molecular development of the kidney: a review of the results of gene disruption studies. Am J Kidney Dis 31: 383–397. 67. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265–273. 68. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, et al. (2008) Pathway analysis of primary central nervous system lymphoma. Blood 111: 3200–3210. 69. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868. PLoS ONE | www.plosone.org 14 May 2010 | Volume 5 | Issue 5 | e10696